24/7 Market News Snapshot 09 December, 2024 – AngioDynamics, Inc. (NASDAQ:ANGO)

December 9, 2024

DENVER, Colo., 09 December, 2024 (247marketnews.com) – (NASDAQ:ANGO) are discussed in this article.
AngioDynamics, Inc. has experienced a significant surge in its stock value, opening at $7.44 and reaching $8.79, reflecting a remarkable increase of 25.61% compared to yesterday’s closing price of $7.00. This upward momentum is indicative of strong investor confidence, demonstrated by a notable trading volume of 2.78 million shares. This positive market response culminates at a pivotal moment for the company following its recent announcement of FDA 510(k) clearance for the NanoKnife System, an innovative device intended for the treatment of intermediate-risk prostate cancer.

The FDA approval of the NanoKnife System is a considerable milestone for AngioDynamics, following the successful completion of the pivotal PRESERVE clinical study, which highlighted the system’s safety and effectiveness in ablating prostate tissue. Involving 121 patients across 17 clinical sites, the study revealed encouraging results, with 84% of participants remaining free from clinically significant disease at the 12-month follow-up. Moreover, essential quality of life metrics, including urinary continence and erectile function, were largely maintained, underscoring the device’s potential to enhance patient outcomes.

Jim Clemmer, President and CEO of AngioDynamics, emphasized the company’s commitment to delivering innovative therapies that prioritize favorable function-preserving results. The NanoKnife utilizes Irreversible Electroporation (IRE) technology, presenting a non-thermal, radiation-free solution that selectively targets and eliminates malignant cells while safeguarding surrounding healthy tissue. As prostate cancer remains the second most prevalent cancer among men worldwide, the introduction of the NanoKnife System addresses a critical need for alternative treatments that mitigate long-term complications associated with traditional surgical interventions.

Looking ahead, AngioDynamics is set to launch comprehensive educational initiatives for healthcare professionals to facilitate understanding and adoption of the NanoKnife System. This strategic endeavor positions the company to redefine prostate health care standards and improve patient outcomes significantly.

Related news for (ANGO)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.